Patents by Inventor Xavier PRÉVILLE

Xavier PRÉVILLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF
    Publication number: 20240034791
    Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
    Type: Application
    Filed: March 31, 2022
    Publication date: February 1, 2024
    Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –
    Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
  • IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY
    Publication number: 20240024437
    Abstract: The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).
    Type: Application
    Filed: December 28, 2022
    Publication date: January 25, 2024
    Applicant: Transgene SA
    Inventors: Philippe SLOS, Julie Hortelano, Karola Rittner, Xavier Preville
  • CD96-BINDING AGENTS AS IMMUNOMODULATORS
    Publication number: 20230192845
    Abstract: Provided is a CD96-binding agent, wherein the agent is capable of stimulating activation and/or proliferation of T cells upon binding to CD96. Also provided are isolated nucleic acids and cells that produce the agent and uses thereof.
    Type: Application
    Filed: August 10, 2018
    Publication date: June 22, 2023
    Applicants: BLINK BIOMEDICAL SAS, TALIX THERAPEUTICS NV
    Inventors: Florence Renart-Depontieu, Sachiko Takami, Germain Margall-Ducos, Nicola Beltraminel-Li, Pierre Garrone, Anne Rogel, Aymen Al-Shamkhani, Xavier Preville
  • COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS
    Publication number: 20200376052
    Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising said oncolytic virus and said one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and said one or more immune checkpoint modulator(s).
    Type: Application
    Filed: August 5, 2020
    Publication date: December 3, 2020
    Applicants: Institut Gustave-Roussy, Transgene SA
    Inventors: Laurence Zitvogel, Xavier Preville, Laetitia Fend
  • Combination of oncolytic virus with immune checkpoint modulators
    Patent number: 10765710
    Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising an oncolytic virus and one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of an oncolytic virus and one or more immune checkpoint modulator(s).
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: September 8, 2020
    Assignees: Institut Gustave-Roussy, Transgene SA
    Inventors: Laurence Zitvogel, Xavier Preville, Laetitia Fend
  • IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY
    Publication number: 20180028626
    Abstract: The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).
    Type: Application
    Filed: February 12, 2016
    Publication date: February 1, 2018
    Applicant: Transgene SA
    Inventors: Philippe Slos, Julie Hortelano, Karola Rittner, Xavier Preville
  • COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS
    Publication number: 20170143780
    Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising said oncolytic virus and said one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and said one or more immune checkpoint modulator(s).
    Type: Application
    Filed: July 16, 2015
    Publication date: May 25, 2017
    Applicants: Institut Gustave-Roussy, Transgene SA
    Inventors: Laurence Zitvogel, Xavier Preville, Laetitia Fend
  • Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
    Patent number: 9486524
    Abstract: The present invention relates to a composition for eliciting a specific cytotoxic T lymphocyte (CTL) response against T cell epitopes in a mammal, which comprises a compound provoking lymphocytopenia, a molecule having selective affinity for professional antigen presenting cells (APC), wherein said molecule is associated to said T cell epitope, and optionally, a pharmaceutical acceptable carrier. Advantageously, the composition further contains an adjuvant. Said composition may be used in anti-infections and anti-cancer therapies.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: November 8, 2016
    Assignee: GENTICEL
    Inventors: Xavier Preville, Benedikt Timmerman
  • Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
    Publication number: 20110097337
    Abstract: The present invention relates to a composition for eliciting a specific cytotoxic T lymphocyte (CTL) response against T cell epitopes in a mammal, which comprises a compound provoking lymphocytopenia, a molecule having selective affinity for professional antigen presenting cells (APC), wherein said molecule is associated to said T cell epitope, and optionally, a pharmaceutical acceptable carrier. Advantageously, the composition further contains an adjuvant. Said composition may be used in anti-infections and anti-cancer therapies.
    Type: Application
    Filed: August 31, 2007
    Publication date: April 28, 2011
    Inventors: Xavier Preville, Benedikt Timmerman